PE20110772A1 - ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 - Google Patents

ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3

Info

Publication number
PE20110772A1
PE20110772A1 PE2011001198A PE2011001198A PE20110772A1 PE 20110772 A1 PE20110772 A1 PE 20110772A1 PE 2011001198 A PE2011001198 A PE 2011001198A PE 2011001198 A PE2011001198 A PE 2011001198A PE 20110772 A1 PE20110772 A1 PE 20110772A1
Authority
PE
Peru
Prior art keywords
oxazolidinones
azepan
spiro
channel blockers
potassium channel
Prior art date
Application number
PE2011001198A
Other languages
English (en)
Inventor
Pieter Smid
Michael Mlinaric
Josephus H M Lange
Konrad F Koehler
Sara Nunez-Garcia
Elmar Wegener
Original Assignee
Abbott Healthcare Products Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Healthcare Products Bv filed Critical Abbott Healthcare Products Bv
Publication of PE20110772A1 publication Critical patent/PE20110772A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A COMPUESTOS DERIVADOS DE ESPIRO AZEPAN OXAZOLIDINONAS (1-OXA-3,8-DIAZAESPIRO[4.6]UNDECAN-2-ONAS) DE FORMULA (1) DONDE R1 Y R2 SON CADA UNO H, F, CF3 O ALQUILO(C1-C3); n ES DE 0 A 2; R3 ES HALOGENO, ALQUILO(C1-C3), CN, NH2, ENTRE OTROS; m ES DE 0 A 3; R4 ES HALOGENO, CN, OH, OCH3, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (5S)-8-[3,5-BIS(TRIFLUOROMETIL)BENZOIL]-3-[(1S)-1-FENILETIL]-1-OXA-3,8-DIAZAESPIRO[4.6]-UNDECAN-2-ONA; (5R)-8-[3-CIANOBENZOIL]-3-[(1S)-1-FENILETIL]-1-OXA-3,8-DIAZAESPIRO[4.6]UNDECAN-ONA; ENTRE OTROS. TAMBIEN SE REFIERE A UN PROCEDIMIENTO DE PREPARACION Y A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS SON BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 VOLTAJE DEPENDIENTE SIENDO UTILES EN EL TRATAMIENTO DE DIABETES, NEUROPATIAS INFLAMATORIAS, ARTRITIS REUMATOIDE, ESCLEROSIS MULTIPLE
PE2011001198A 2008-12-12 2009-12-10 ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3 PE20110772A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12191308P 2008-12-12 2008-12-12
EP08171421 2008-12-12

Publications (1)

Publication Number Publication Date
PE20110772A1 true PE20110772A1 (es) 2011-10-19

Family

ID=40513443

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001198A PE20110772A1 (es) 2008-12-12 2009-12-10 ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3

Country Status (20)

Country Link
US (1) US8575148B2 (es)
EP (1) EP2376501A1 (es)
JP (1) JP2012511546A (es)
KR (1) KR20110110165A (es)
CN (1) CN102333782A (es)
AR (1) AR074558A1 (es)
AU (1) AU2009324358A1 (es)
BR (1) BRPI0922714A2 (es)
CA (1) CA2743557A1 (es)
CO (1) CO6390036A2 (es)
CR (1) CR20110302A (es)
DO (1) DOP2011000164A (es)
EA (1) EA201170801A1 (es)
EC (1) ECSP11011118A (es)
IL (1) IL212948A0 (es)
MX (1) MX2011006221A (es)
PE (1) PE20110772A1 (es)
TW (1) TW201026708A (es)
WO (1) WO2010066840A1 (es)
ZA (1) ZA201104041B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014531469A (ja) * 2011-10-03 2014-11-27 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、カ Ｋｖ１．３カリウムチャネルの薬理学的標的化による肥満症および肥満症関連障害の治療
MA38135B1 (fr) * 2012-10-29 2018-11-30 Hoffmann La Roche Dérivés d'oxazolidinone 3,4-disubstituée et leur utilisation comme inhibiteurs des canaux potassiques activés par le calcium
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
CN109053751A (zh) * 2018-08-30 2018-12-21 成都海博锐药业有限公司 具有螺环结构的fxr调节剂
US20220356176A1 (en) * 2019-06-12 2022-11-10 The Johns Hopkins University Kv11.1-3.1 INHIBITING METHODS AND COMPOSITIONS
CN111574537B (zh) * 2020-05-20 2022-11-15 成都药明康德新药开发有限公司 叔丁基-8-氧杂-3,11-二氮杂螺[5.6]十二烷-3-甲酸基酯的合成方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors

Also Published As

Publication number Publication date
CO6390036A2 (es) 2012-02-29
TW201026708A (en) 2010-07-16
ECSP11011118A (es) 2011-07-29
ZA201104041B (en) 2012-11-28
US20110237569A1 (en) 2011-09-29
EP2376501A1 (en) 2011-10-19
WO2010066840A1 (en) 2010-06-17
BRPI0922714A2 (pt) 2016-01-05
AU2009324358A1 (en) 2011-06-23
US8575148B2 (en) 2013-11-05
MX2011006221A (es) 2011-06-28
IL212948A0 (en) 2011-07-31
KR20110110165A (ko) 2011-10-06
CR20110302A (es) 2011-10-27
CN102333782A (zh) 2012-01-25
DOP2011000164A (es) 2011-06-30
AR074558A1 (es) 2011-01-26
CA2743557A1 (en) 2010-06-17
EA201170801A1 (ru) 2011-12-30
JP2012511546A (ja) 2012-05-24

Similar Documents

Publication Publication Date Title
PE20110772A1 (es) ESPIRO AZEPAN OXAZOLIDINONAS COMO BLOQUEADORES DEL CANAL DE POTASIO Kv1.3
PE20141004A1 (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
PE20090222A1 (es) Compuestos [6,6] y [6,7]-biciclicos como agonistas del receptor acoplado a la proteina g gpr119
PE20081753A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
PE20142452A1 (es) AMIDAS CICLICAS COMO INHIBIDORES DE MetAP-2
PE20110028A1 (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotropicos de glutamato
PE20141005A1 (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
PE20131197A1 (es) Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20141588A1 (es) Nuevos derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2
PE20130576A1 (es) Compuestos heterociclicos de nitrogeno utiles como inhibidores de pde10
PE20070720A1 (es) Derivados de fenilo como antagonistas del receptor 3 de la histamina
PE20140623A1 (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace2
PE20081345A1 (es) Compuestos heterociclicos que contienen nitrogeno como agonistas del receptor nicotinico
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
PE20140240A1 (es) Antagonistas del receptor del cgrp de piperidinona carboxamida azaindano
PE20140161A1 (es) Compuesto biciclico
PE20080274A1 (es) Derivados de dioxo-alcanos y dioxo-alquenos sustituidos como moduladores del receptor vanilloide subtipo 1 (trpv1)
PE20110819A1 (es) Compuestos de carbazol carboxamida utiles como inhibidores de cinasa
PE20141685A1 (es) Novedosas dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de transtornos inflamatorios
PE20081229A1 (es) Antagonistas de receptor de orexina de diazepam sustituido
PE20161396A1 (es) Compuesto heterociclico
PE20110196A1 (es) 5-alquinil-pirimidinas
PE20142376A1 (es) Fluormetil-5,6-dihidro-4h-[1,3]oxazinas
PE20141578A1 (es) Derivados de [1,2,3]triazolo[4,5-d]pirimidina como agonistas del receptor de canabinoides 2

Legal Events

Date Code Title Description
FD Application declared void or lapsed